BACKGROUND Scarce data exist on the incidence of and factors associated with valve hemodynamic deterioration
S
tructural valve degeneration (SVD) is the main cause of bioprosthetic valve failure after surgical aortic valve replacement (SAVR). The reported incidence of SVD after SAVR at 1, 10, and 15 years has been <1%, 10% to 30%, and 20% to 50%, respectively (1) (2) (3) . These data traditionally have been determined on the basis of the incidence of reoperation after surgical bioprosthetic valve failure.
However, this approach may underestimate the true incidence of SVD (4, 5) , and several studies have proposed to define SVD occurrence according to the development of valve hemodynamic dysfunction documented by Doppler echocardiography (6) (7) (8) . as documented by Doppler echocardiography may be related to calcific degeneration of bioprosthetic valve leaflets (i.e., SVD), but it may also result from thrombosis or pannus ingrowth.
Transcatheter aortic valve replacement (TAVR) is
well established for treating patients with symptomatic severe aortic stenosis who are at high or prohibitive surgical risk (9) . Although SVD requiring valve replacement is a rare entity within the first years after TAVR (10, 11) , scarce data exist on subclinical bioprosthetic hemodynamic dysfunction after TAVR.
Investigators have suggested that rapid changes in transvalvular gradients may be the hallmark of valve thrombosis despite the absence of clinical symptoms (12) (13) (14) . Given that antithrombotic or anticoagulation therapies post-TAVR are not currently well established, it is of the utmost importance to determine whether subclinical valve thrombosis could be an underlying pathophysiological mechanism contributing to transcatheter valve failure. We aimed to establish the incidence and risk factors of VHD within a large population of patients who had undergone TAVR.
METHODS
Between May 2007 and October 2014, 2,418 consecutive patients underwent TAVR in 10 participating centers. Patients were considered eligible for this multicenter study if they had undergone at least 2 echocardiograms post-TAVR (at discharge and at a minimum of 6-to 12-month follow-up). A total of 1,521 patients satisfied these criteria and were included in our study. Eligibility for TAVR, valve type, and access route were determined at each center by a local heart team composed of interventional cardiologists and cardiac surgeons. Clinical, procedural, and echocardiographic data were prospectively gathered within a TAVR database at each participating center. This study was not a prespecified analysis at the time of the creation of the database; therefore, data were analyzed retrospectively. Clinical follow-up was undertaken during clinical visits or through telephone contact, or both, at 1 month post-TAVR, at 6 to 12 months post-TAVR, and yearly thereafter in all participating centers.
Clinical events were prospectively recorded and defined according to VARC-2 (Valve Academic Research Consortium-2) criteria (15) .
ECHOCARDIOGRAPHIC ASSESSMENT. Transthoracic echocardiography (TTE) examinations were performed at baseline, at hospital discharge, at 6 to 12 months post-TAVR, and yearly thereafter.
All TTE examinations were conducted according to American Society of Echocardiography guidelines (16, 17) . Peak transprosthetic flow velocity was determined by continuous-wave Doppler imaging. The mean transprosthetic gradient was calculated using the modified Bernoulli formula.
Absolute change in mean gradient was calculated as the gradient at last follow-up minus the gradient at discharge. Annualized change in mean gradient (mm Hg/year) was calculated by dividing the absolute change in gradient by the time between examinations. VHD was defined as an absolute change in gradient of $10 mm Hg during follow-up (8, 18 Del Trigo et al. 
RESULTS
The main baseline and procedural characteristics of the study population are shown in Values are mean AE SD or n/N (%). *SAPIEN and SAPIEN XT.
BMI ¼ body mass index; CKD ¼ chronic kidney disease; COPD ¼ chronic obstructive pulmonary disease; eGFR ¼ estimated glomerular filtration rate; LVEF ¼ left ventricular ejection fraction; PPM ¼ prosthesis-patient mismatch; VKA ¼ Vitamin K antagonist.
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2 years were more likely to have a previous history of SAVR and chronic kidney disease and to have a greater BMI, and they were more frequently treated with small valves (Online Table 2 ). Given that aortic regurgitation (AR) at discharge may influence mean gradients during follow-up, a subanalysis excluding patients with prosthesis size #23 mm, valve-in-valve, and AR that was moderate to severe, was conducted.
In this subanalysis, the absence of anticoagulation therapy at discharge was the only independent pre- Table 3 ).
An additional analysis was performed to evaluate the factors associated with VHD within the year after TAVR (early VHD), defined as a $10 mm Hg increase in mean transprosthetic gradient within the first year post-TAVR compared with discharge assessment.
A total of 42 patients met criteria for early VHD.
The main clinical and procedural characteristics of patients according to the occurrence of early VHD are shown in Online Tables 1 and 2 . Del Trigo et al.
Valve Hemodynamic Deterioration After TAVR We showed that increment in mean gradient is not a uniform process occurring in all patients undergoing TAVR. In our study, no significant progression of mean transprosthetic gradients was found after exclusion of the 68 patients who demonstrated overt VHD (annualized overall change in mean transprosthetic gradient was À0.2 mm Hg/year for patients without VHD). This finding implies that VHD occurs within a specific subset of patients undergoing TAVR.
Among the patients who satisfied criteria for VHD, only a small proportion received specific treatment.
Additionally, most patients diagnosed with VHD failed to display a continued increase in gradient beyond 1 year (Figure 4) . 18.2%
13.5%
7.1%
3.2%
At 1-year follow-up, there were no significant differences in death (A), cardiovascular death (B), or stroke (C), between patients with or without valve hemodynamic deterioration (VHD).
Valve Hemodynamic Deterioration After TAVR In addition, no significant differences in clinical outcomes were observed in patients with VHD at 1-year follow-up. This finding concurred with previous studies assessing valve thrombosis post-TAVR. In a study using multidetector CT, Leetmaa et al. (24) reported that the incidence of THV thrombosis after TAVR was higher than expected; however, most patients diagnosed with THV thrombosis were asymp- It would be important to use these trial opportunities for embedding pre-specified subanalyses of the changes in transvalvular gradients in these studies.
In addition, VHD could be included as a secondary endpoint in TAVR trials.
Smaller prosthesis size was also an independent risk factor for VHD. As expected, post-implantation Del Trigo et al. Valve Hemodynamic Deterioration After TAVR F E B R U A R Y 1 6 , 2 0 1 6 : 6 4 4 -5 5
